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Abstract
Background: Previous data from our laboratory has indicated that there is a functional link
between the β-adrenergic receptor signaling pathway and the G-protein inwardly rectifying
potassium channel (GIRK1) in human breast cancer cell lines. We wanted to determine if GIRK
channels were expressed in lung cancers and if a similar link exists in lung cancer.
Methods: GIRK1-4 expression and levels were determined by reverse transcription polymerase
chain reaction (RT-PCR) and real-time PCR. GIRK protein levels were determined by western
blots and cell proliferation was determined by a 5-bromo-2'-deoxyuridine (BrdU) assay.
Results: GIRK1 mRNA was expressed in three of six small cell lung cancer (SCLC) cell lines, and
either GIRK2, 3 or 4 mRNA expression was detected in all six SCLC cell lines. Treatment of NCI-
H69 with β2-adrenergic antagonist ICI 118,551 (100 µM) daily for seven days led to slight decreases
of GIRK1 mRNA expression levels. Treatment of NCI-H69 with the β-adrenergic agonist
isoproterenol (10 µM) decreased growth rates in these cells. The GIRK inhibitor U50488H (2 µM)
also inhibited proliferation, and this decrease was potentiated by isoproterenol. In the SCLC cell
lines that demonstrated GIRK1 mRNA expression, we also saw GIRK1 protein expression. We
feel these may be important regulatory pathways since no expression of mRNA of the GIRK
channels (1 & 2) was found in hamster pulmonary neuroendocrine cells, a suggested cell of origin
for SCLC, nor was GIRK1 or 2 expression found in human small airway epithelial cells. GIRK
(1,2,3,4) mRNA expression was also seen in A549 adenocarcinoma and NCI-H727 carcinoid cell
lines. GIRK1 mRNA expression was not found in tissue samples from adenocarcinoma or
squamous cancer patients, nor was it found in NCI-H322 or NCI-H441 adenocarcinoma cell lines.
GIRK (1,3,4) mRNA expression was seen in three squamous cell lines, GIRK2 was only expressed
in one squamous cell line. However, GIRK1 protein expression was not seen in any non-SCLC cells.
Conclusion: We feel that this data may indicate that stimulation of GIRK1 or GIRK2 channels may
be important in lung cancer. Stimulation of GIRK channels and β-adrenergic signaling may activate
similar signaling pathways in both SCLC and breast cancer, but lead to different results.
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Background
Recent studies in human cancer cell lines or in animal
models have shown that the growth of adenocarcinomas
of the lungs, pancreas and colon are under β-adrenergic
control [1-5]. The tobacco carcinogenic nitrosamine 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
has recently been identified as a high affinity β-adrenergic
agonist that stimulated the growth of pulmonary and pan-
creatic adenocarcinomas in vitro and in animal models
[1,3,5]. Expression of mRNA that encodes a G-protein
coupled inwardly rectifying potassium channel (GIRK1)
has been shown in tissue samples from approximately
40% of primary human breast cancers tested [6], and this
expression of GIRK1 was associated with a more aggres-
sive clinical behavior. Increases in GIRK currents by β-
adrenergic stimulation have been reported in adult rat car-
diomyocytes and in Xenopus laevis oocytes coexpressing
β2-adrenergic receptors and GIRK1/GIRK4 subunits [7]. In
addition, in rat atrial myocytes transiently transfected
with β1 or β2 adrenergic receptors, the β-adrenergic agonist
isoproterenol (Iso) stimulated GIRK currents, whereas
this stimulation was not seen in non-transfected cells [8].
Previous data from our laboratory has indicated that there
is a functional link between the β-adrenergic receptor
pathway and the G-protein inwardly rectifying potassium
channel (GIRK1) in breast cancer cell lines and these path-
ways were involved in growth regulation of these cells
[9,10]. Additional data from our laboratory has also indi-
cated that the normal breast epithelial cell line MCF 10A
lacks GIRK1 expression [10].
Established risk factors for breast cancer include age,
increased hormone exposure, alcohol consumption and
family history as well as many other factors [11]. Smoking
is a controversial risk factor for the development of this
malignancy [12-14]. However, increases in pulmonary
metastatic disease have been seen in smokers with breast
cancer [15]. In addition, a study of 141,000 women
showed a significantly increased risk of developing lung
cancer for breast cancer patients, possibly due to interac-
tions between radiotherapy and smoking [16]. An eight-
fold increase in breast cancer risk has been seen in women
who were smokeless tobacco users [17]. Smokeless
tobacco has higher levels of nicotine and the tobacco car-
cinogen NNK than cigarette smoke [18]. However, many
types of lung cancer are smoking related [19].
In order to investigate possible similarities between breast
cancer and lung cancer, we wanted to determine if GIRK
channels are expressed in human lung cancers and if β-
adrenergic signaling is also involved in lung cancer. Volt-
age gated K+, Na+ and Ca2+ channels have been shown in
the small cell lung cancer (SCLC) cell lines NCI-H128,
NCI-H69 and NCI-H146 by measurement of currents
[20]. These voltage activated K+ channels in the SCLC cell
lines have a role in modulating cell proliferation [21]. A
classical inwardly rectifying potassium channel not linked
with G-proteins has been shown in a subclone of NCI-
H69, H69AR, a subline with overexpressed multidrug
resistance associated protein, but these currents were not
seen in the original H69 cell line [22]. Inwardly rectifying
potassium currents have also been measured in RERF-LC-
MA SCLC cells, and these cells express the Kir2.1 mRNA
and protein [23]. GIRK1 expression has been shown in tis-
sue specimens from patients with non-small lung cancer
and this expression was associated with lymph node
metastasis [24]. Prior to this study, GIRK channels have
not been identified in lung cancer cell lines or SCLC cell
lines and clinical samples. In the present research we have
screened small cell and non-small cell lung cancer cell
lines and several normal lung cell types for GIRK mRNA
and protein expression.
Methods
Cell culture
The human SCLC cell lines NCI-H69 (H69), NCI-H146
(H146), NCI-H187 (H187), NCI-H209 (H209), and NCI-
H526 (H526), the human adenocarcinoma cell lines NCI-
H322 (H322), NCI-H441 (H441), and A549, the carci-
noid cell line NCI-H727 (H727), and the squamous cell
lines NCI-H226 (H226), NCI-H2170 (H2170), and NCI-
H520 (H520) were purchased from the American Type
Culture Collection (Manassas, VA). The human SCLC cell
line WBA [25] was a gift of Dr. G. Krystal, Medical College
of Virginia. All cancer cell lines except A549 were main-
tained in RPMI medium supplemented with fetal bovine
serum (10% v/v), L-glutamine (2 mM), penicillin (100 U/
ml) and streptomycin (100 µg/ml) at 37°C in an atmos-
phere of 5% CO2. A549 cells were grown in Hams F12
media with supplements as above. Human small airway
epithelia cells (SAEC) were purchased from Clonetics/
BioWhittaker (Walkersville, MD). These primary cells
were maintained in SAEC basal medium with supple-
ments (Clonetics) at 37°C in an atmosphere of 5% CO2.
Fresh surgical tissue samples were collected from patients
at the University of Tennessee (UT) Graduate School of
Medicine's Cancer Center and processed for reverse tran-
scription polymerase chain reaction (RT-PCR). The collec-
tion of tissue was approved by the UT Institutional Review
Board, and the authors have been certified by the NIH
Office of Human Subjects Research. Cultures of fetal ham-
ster pulmonary neuroendocrine cells (PNEC) were estab-
lished from fetal lung periphery harvested on day 15 of
gestation as previously described [26,27]. Studies with
fetal hamster cells were approved by the UT Institutional
Animal Care and Use Committee. Exposure of cells to iso-
proterenol (Iso), the GIRK inhibitor U50488H (U5) [28]
(Sigma, St. Louis, MO), or ICI 118,551 (ICI) (Tocris, Ball-
win, MO) for experiments was as detailed in the figure leg-
ends or results.
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RT-PCR
RNA from cell cultures, adult hamster brain, PNEC and
from fresh surgical tissue samples was isolated by guani-
dine isothiocyanate/cesium chloride ultracentrifugation
[29] or by an Absolutely RNA kit (Stratagene, La Jolla,
CA). RT-PCR was done as previously described [10]. The
GIRK3 primers are forward 5'-gtgaccagcttcctccagac-3' and
reverse 5'-gctaccatcttcccatccaa-3' which amplifies a 317 bp
fragment (bases 1421–1737, Genbank Acession #
NM_004983). PCR conditions are 94°C, 30 sec; 55°C, 30
sec; 72°C, 45 sec for 40 cycles. Cyclophilin primers were
used an internal control (Ambion, Austin, TX).
Real-time PCR
Real-time PCR was done as previously described [10].
GIRK1 primers-forward 5'-ctctcggacctcttcaccac-3' and
reverse 5'-gccacggtgtaggtgagaat-3' (bases 398–477, Gen-
bank Acession # NM002239) and the internal TaqMan
probe is 6-FAM-tcaagtggcgctggaacctc-TAMRA (bases 429–
449), annealing 62°. GIRK2 primers-forward 5'-gacct-
gccaagacacatcag-3' and reverse 5'-cggtcaggtagcgataggtc-3'
(bases 766–886, Genbank Acession # U52153) and the
internal TaqMan probe is 6-FAM-gtgcaatgttcatcacggcaac-
TAMRA (bases 837–859), annealing 56°. GIRK4 primers-
forward 5'-agcgctacatggagaagagc-3' and reverse 5'-aagtt-
gaagcgccacttgag-3' (bases 241–358, Genbank Acession #
L47208) and the internal TaqMan probe is 6-FAM-accgg-
tacctgagtgacctcttca-TAMRA (bases 301–324), annealing
62°. Reactions were run on a Cepheid SmartCycler (Sun-
nyvale, CA). Reaction conditions are 200 µM dNTPs, 0.3
µM gene specific primers, 0.2 µM TaqMan probe, 4 mM
(GIRK1) or 6 mM (GIRK2or4) magnesium acetate, 2 µl
cDNA and 1.5 U MasterTaq (Eppendorf, Westbury, NY)
and MasterTaq buffer in a final volume of 25 µl. In some
experiments, 18S primers were used an internal control
(Qiagen, Valencia, CA).
Proliferation assay
Cells were counted and plated in RPMI without serum or
phenol red at a density of 50,000 cells/well with appropri-
ate treatments in a volume of 500 µl. Cells were allowed
to grow for 48 hours, and proliferation was measured by
a cell proliferation assay for 5-bromo-2'-deoxyuridine
(BrdU) according to the manufacturer's instructions
(Roche, Indianapolis, IN), N = 5 for each treatment group.
Western blots
Cell pellets were collected and membrane protein was iso-
lated with the ReadyPrep protein extraction kit (signal)
(Biorad, Hercules, CA). Protein levels were determined
using the RCDC kit (Biorad). Aliquots of 20–30 µg pro-
tein were boiled in 3× loading buffer (New England
Biolabs, Beverly, MA) for two minutes, then loaded onto
12% Tris-glycine-polyacrylamide gels (Cambrex, Rock-
land, ME), and transferred electrophoretically to nitrocel-
lulose membranes. Membranes were incubated with the
primary antibody (GIRK1; Upstate Biotechnology, Lake
Placid, NY). In all western blots, membranes were addi-
tionally probed with an antibody for actin (Sigma) to
ensure equal loading of protein between samples. The
membranes were then incubated with appropriate sec-
ondary antibodies (Rockland, Gilbertsville, PA or Molec-
ular Probes, Eugene OR). The antibody-protein
complexes were detected by the LiCor Odyssey infrared
imaging system (Lincoln, NE).
Results
In order to investigate possible expression similarities
between breast cancer and lung cancer, we wanted to
determine if GIRK channels are expressed in human lung
cancers. Expression of mRNA for the GIRK1 channel was
seen in three of six SCLC cell lines. GIRK 1 was expressed
in the SCLC cell lines H69, H146 and WBA (Figure 1).
Since GIRK1 cannot form channels alone, it must assem-
ble with GIRK2, 3 or 4 [reviewed in [30]]. GIRK2 & 4
expression was determined in the six SCLC cell lines using
real-time PCR. GIRK 4 expression was found in all six
SCLC cell lines, and GIRK2 was found in all six SCLC cell
lines with the exception of H146 and H187 (Table 1). In
these experiments, real-time PCR was used as a second
method of determining gene expression. Since gene
expression was determined by only one sample (similar to
gene expression studies by RT-PCR) no comparisons can
be made between CT values for the samples. We wished to
compare GIRK1 expression in SCLC to normal primary
cells. GIRK1 was not expressed in the normal human SAE
cells (Figure 1). Normal SAE cells express GIRK4 but do
not express GIRK2 (data not shown). SCLC shares pheno-
typic and functional features with pulmonary neuroendo-
crine cells (PNEC), one of the possible origins of this
cancer type [31]. Neither GIRK1 nor GIRK2 mRNA expres-
sion was found in normal tissue from PNEC cells isolated
from prenatal hamster lungs using the primers designed
for human GIRK1 and 2 (Figure 2). In order to determine
if this result was due to species differences in GIRK1 and
2 between humans and hamsters, tissue was isolated from
hamster brain. In both cases, mRNA from GIRK1 and 2
were found to be expressed in hamster brain (Figure 2).
However, our GIRK4 primers were found not to work in
hamster tissue (data not shown).
We wanted to determine if GIRK channels were also
expressed in human non-SCLC (NSCLC) cancers. GIRK1
was not expressed in two adenocarcinoma cell lines of
Clara cell phenotype, H322 and H441 (Figure 1). How-
ever, three GIRK channels (1,2,4) were expressed in both
the human adenocarcinoma cell line with alveolar type II
cell phenotype (A549) and human carcinoid cell line
expressing neuroendocrine features (H727) (Figure 3).
GIRK1 and 4 are expressed in three squamous cell lines,
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H2170, H226, and H520 (Figure 4). GIRK2 is only
expressed in the H520 cell line, but not in either H2170
or H226 cell lines (Figure 4).
Although the predominant GIRK heterotetramers seem to
be GIRK1/2 and GIRK1/4 [reviewed in [30]], GIRK3
expression may also be important in lung cancer. GIRK3
expression in normal cells, SCLC cell lines and NSCLC cell
lines was examined. GIRK3 expression was seen in all six
SCLC cell lines (Figure 5). GIRK3 was expressed in normal
cells (SAEC, PNEC) and in the five NSCLC cell lines
(A549, H727, H2170, H226, H520) (Figure 6). A sum-
mary of all the above experiments indicating gene expres-
sion data for the cell lines and normal cells is shown in
Table 2. We also wanted to determine if GIRK1 was
expressed in fresh surgical tissue samples. A limited
number of samples of pulmonary adenocarcinomas
(three) or pulmonary squamous carcinomas (two) were
Expression of GIRK1 in some SCLC cell lines but not in nor-mal SAE cells, nor in adenocarcinoma Clara cell phenotype cel linesFigur  1
Expression of GIRK1 in some SCLC cell lines but not 
in normal SAE cells, nor in adenocarcinoma Clara 
cell phenotype cell lines. Top panel: GIRK1 is expressed 
in WBA, H69, and H146 SCLC cell lines but not in H187, 
H209 and H526 SCLC cell lines. GIRK1 is also not expressed 
in normal SAE cells, nor is it expressed in H322 or H441 
adenocarcinoma Clara cell lines. Bottom panel: Cyclophilin, 
used as a positive reaction control was seen in all samples. 
For all gene expression experiments, negative control reac-
tions were performed and found to be negative. The bands 
on the agarose gels were consistent with the expected sizes: 
GIRK1-441 bp; cyclophilin-216 bp; M-100 bp.
Table 1: Expression of GIRK2 or GIRK4 in small cell lung cancer 
cell lines. Expression of either GIRK2 or GIRK4 was determined 
by real time PCR. Threshold values (CT) values are listed below.
Cell Line GIRK2 GIRK4
WBA 19.82 30.56
H69 23.54 32.18
H146 NF 40.54
H187 NF 31.60
H209 24.53 24.64
H526 27.55 23.21
NF – No CT value calculated due to lack of expression. Gene 
expression was determined by one sample. No comparisons can be 
made between CT values for the samples.
Lack of GIRK1 and 2 expression in hamster PNEC cellsFigure 2
Lack of GIRK1 and 2 expression in hamster PNEC 
cells. Top panel: Pulmonary neuroendocrine cells were iso-
lated from fetal hamsters on the 15th day of gestation. Nei-
ther GIRK1 nor GIRK2 was expressed in normal PNEC. 
Bottom panel: Tissue was isolated from adult hamster brain 
to determine if the lack of expression in PNEC was not due 
to species differences in PCR primers. Both GIRK1 and 
GIRK2 were expressed in hamster brain. Cyclophilin, used as 
a positive reaction control was seen in the samples. For all 
gene expression experiments, negative control reactions 
were performed and found to be negative. The bands on the 
agarose gels were consistent with the expected sizes: 
GIRK1-441 bp; GIRK2-438 bp; cyclophilin-216 bp, M-100 bp.
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Expression of GIRK channels in adenocarcinoma alveolar type II cell phenotype (A549) and carcinoid (H727) cel  linesFigure 3
Expression of GIRK channels in adenocarcinoma 
alveolar type II cell phenotype (A549) and carcinoid 
(H727) cell lines. Top panel: GIRK1 was expressed in both 
A549 and H727 cell lines. Bottom panel: Both A549 and 
H727 expressed GIRK2 and GIRK4. Cyclophilin, used as a 
positive reaction control was seen in both samples. For all 
gene expression experiments, negative control reactions 
were performed and found to be negative. The bands on the 
agarose gels were consistent with the expected sizes: 
GIRK1-441 bp; GIRK2-438 bp; GIRK4-401 bp; cyclophilin-
216 bp; M-100 bp.
Differences in GIRK expression in three squamous carci-noma cell linesFigu  4
Differences in GIRK expression in three squamous 
carcinoma cell lines. Top panel: GIRK1 was expressed in 
all three squamous cell lines, H2170, H226, and H520. Middle 
panel: GIRK2 is only expressed in H520 cell line, but not in 
H2170 or H226. GIRK4 was expressed in all three squamous 
cell lines, H2170, H226, and H520. Bottom panel: Cyclophi-
lin, used as a positive reaction control was seen in all sam-
ples. For all gene expression experiments, negative control 
reactions were performed and found to be negative. The 
bands on the agarose gels were consistent with the expected 
sizes: GIRK1-441 bp; GIRK2-438 bp; GIRK4-401 bp; cyclo-
philin-216 bp; M-100 bp.
BMC Cancer 2005, 5:104 http://www.biomedcentral.com/1471-2407/5/104
Page 6 of 10
(page number not for citation purposes)
collected from patients at the UT Graduate School of
Medicine's Cancer Center. None of these tissue samples
expressed GIRK1 (Figure 7).
For functional GIRK channels in lung cells, protein expres-
sion is needed as well as gene expression. We determined
GIRK1 protein expression in cell lines that express GIRK1
mRNA. Isolating enriched membrane protein using a Bio-
rad kit, we found GIRK1 protein expression in the three
SCLC cell lines that expressed GIRK1 mRNA, H69, H146
and WBA (Figure 8). In addition, in the NSCLC cell lines
that express GIRK1 mRNA, GIRK1 protein expression was
determined. GIRK1 protein expression was not seen in
A549, H727, H2170, H226, and H520 (data not shown).
Since β-adrenergic ligands affected both gene expression
of GIRK1 and cell proliferation for breast cancer cell lines
in our laboratory [10], we wanted to determine if β-adren-
ergic agonists and antagonists had effects on either gene
expression or cell proliferation in SCLC cells. H69 cells
were used for these experiments because it is one of the
two cell lines that expressed mRNA for all four GIRK chan-
nels as well as GIRK1 protein. The second cell line, WBA,
is not as well characterized in the literature. Exposure of
MDA-MB-453 breast cancer cells for six days to the β-
adrenergic antagonist propranolol increased the GIRK1
mRNA levels [10]. In the present experiments, we used
two specific β-adrenergic antagonists to possibly induce
changes in GIRK1 mRNA levels. The specific β1 antagonist
atenolol (100 µM) had no effect on gene expression when
H69 cells were treated for seven days (Table 3). However,
when H69 cells were treated with 100 µM of the β2 adren-
ergic antagonist ICI daily for seven days, differences in
gene expression were seen as determined by real-time
quantitative PCR (Table 3). Calculating differences in
gene expression using the 2-∆∆CT Formula [32], ICI treat-
ment caused a 1.47× decrease in GIRK1 gene expression p
< 0.0003 (Table 3). H69 cells express mRNA for both β1
and β2 (data not shown). As indicated above, we wanted
to determine if β-adrenergic ligands altered proliferation
in H69 cells. We determined the effects of the β-adrenergic
agonist Iso and the GIRK channel inhibitor U5 [28] on
proliferation in H69 cells. Iso (10 µM) inhibited prolifer-
ation (p < 0.001) (Figure 9). The GIRK inhibitor U5 (2
µM) also inhibited proliferation (p < 0.001), and this
decrease was potentiated by Iso (p < 0.001) (Figure 9).
Discussion
This is the first report that describes the expression of
mRNA for G-Protein Inwardly Rectifying Potassium
Channels (GIRKs) in lung cancer cell lines. Previous
reports have indicated that voltage gated K+, Na+ and Ca2+
channels have been shown in SCLC cell lines [20], and
these voltage activated K+ channels have a role in modu-
lating cell proliferation [21]. Classical inwardly rectifying
potassium channels not linked with G-proteins have been
shown in a few SCLC cell lines [22,23]. Since GIRK1 can-
not form functional channels by itself, other GIRK chan-
nels are needed [30]. All six SCLC cell lines tested express
mRNA for either GIRK2 or GIRK4 indicating that func-
tional GIRK potassium channels are possible in these
SCLC cancer cell lines. GIRK1 has been shown in tissue
samples from approximately 40% of primary human
Expression of GIRK3 in SCLC cell linesFigure 5
Expression of GIRK3 in SCLC cell lines. Top panel: 
GIRK3 expression was seen in all six SCLC cell lines, in 
WBA, H69, H146, H187, H209, and H526. Bottom panel: 
Cyclophilin, used as a positive reaction control was seen in 
all samples. For all gene expression experiments, negative 
control reactions were performed and found to be negative. 
The bands on the agarose gels were consistent with the 
expected sizes: GIRK3-317 bp; cyclophilin-216 bp; M-100 bp.
GIRK3 expression in NSCLC cell lines and in normal cellsFigure 6
GIRK3 expression in NSCLC cell lines and in normal 
cells. Top panel: GIRK3 was expressed in normal human 
SAEC and hamster PNEC as well as being expressed in all 
NSCLC cell lines tested. These NSCLC cell lines are: A549, 
H727, H226, H520, and H2170. Bottom panel: Cyclophilin, 
used as a positive reaction control was seen in all samples. 
For all gene expression experiments, negative control reac-
tions were performed and found to be negative. The bands 
on the agarose gels were consistent with the expected sizes: 
GIRK3-317 bp; cyclophilin-216 bp; M-100 bp.
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breast cancers tested [6], and this expression of GIRK1 was
associated with a more aggressive clinical behavior.
GIRK1 has also been shown to contribute to tumor pro-
gression in NSCLC human tumors [24].
Differences in GIRK channel mRNA expression was seen
in different types of lung cancer. The three adenocarcino-
mas from the lung cancer patient samples did not express
GIRK1, and a subset of lung adenocarcinoma cell lines
(H322, H441) also did not express GIRK1. However,
GIRK1 expression was seen in an adenocarcinoma cell
line with alveolar type II cell phenotype (A549). These
variations may be due to differences between the Clara
cell and the alveolar type II lineage, or it may be due to the
small sample size. The cell linage of the lung cancer
patient samples is unknown. Data from our laboratory
has also indicated differences in responses to anticancer
agents between alveolar type II and Clara cells in the lungs
[33]. Further research with additional cell lines and tissue
samples is needed to determine if the differences in GIRK
expression between alveolar type II cells and Clara cells is
significant.
The two samples from squamous cancer patients also did
not express GIRK1 mRNA. However, squamous
carcinoma cells lines and a carcinoid cell lines do express
GIRK1. In all NSCLC cell lines that express GIRK1, either
GIRK2 or GIRK4 mRNA was expressed, indicating that
functional GIRK potassium channels are possible in these
non-SCLC cancer cell lines. Our data showing lack of
GIRK1 expression in tumors from human adenocarcino-
mas and squamous cell carcinomas in is in contrast to
Takanami et al. [24]. They found that in 72 NSCLC
patients, 69% had high GIRK1 levels and 31% had low
GIRK1 levels [24]. The differences may be due to our
small sample size, or there may be other factors in cancer
patients that affect GIRK1 expression. The expression of
GIRK2 or GIRK4 has not been determined in previous
studies.
The mRNA for GIRK1 & GIRK2 channels have not been
detected in the normal cell lines tested, although the
mRNA for GIRK4 channels was found in SAE normal cells.
Our data indicates more differential expression of GIRK1
and GIRK2 than of GIRK4 in both SCLC and NSCLC cell
lines. It is our hypothesis that GIRK4 is less important in
lung cancer due to the fact it was expressed in all normal
and cancerous cell lines. Further study is needed to
determine the importance of GIRK1 and GIRK2 in lung
cancer. In addition GIRK3 was found in all cell lines
tested, including SAEC and normal hamster PNEC. Since
GIRK3 expression was seen in all cells tested, we also feel
it is unlikely to be a factor in tumor growth or progression.
This hypothesis is supported by data indicating that one
of the functions of GIRK3 is to inhibit plasma membrane
Table 2: Summary of GIRK mRNA expression in lung cells. This is a compilation of data shown in Figures 1–6 & Table 1. Some of the 
indicated data was not shown.
GIRK1 GIRK2 GIRK3 GIRK4
Normal primary
SAEC NF NF E E
PNEC NF NF E X
SCLC
WBA E E E E
H69 E E E E
H146 E NF E E
H187 NF NF E E
H209 NF E E E
H526 NF E E E
NSCLC
H322 NF ND ND ND
H441 NF ND ND ND
H549 E E E E
H727 E E E E
H2170 E NF E E
H226 E NF E E
H520 E E E E
E – mRNA expression
NF – mRNA expression not found
ND – mRNA expression not determined
X – human primer not compatible with hamster
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expression of other GIRK subunits [34]. Further studies
are needed to determine the role of GIRK3 in lung cancer.
Since protein expression would also be necessary for func-
tional GIRK channels, we determined GIRK1 protein
expression in cell lines that expressed GIRK1 mRNA.
Expression of GIRK1 protein was seen in the three SCLC
cell lines that express GIRK1 mRNA. This is the first report
of GIRK1 protein expression in SCLC cell lines. We also
determined GIRK1 protein expression in NSCLC cell
lines. None of the NSCLC cell lines that expressed GIRK1
showed protein expression for GIRK1. We feel that this
indicates that GIRK1 expression may be a larger factor in
SCLC than in NSCLC. Further study is needed to elucidate
these differences.
In the present study, we demonstrated a small decrease in
GIRK1 mRNA expression (1.5×) in the H69 SCLC cell line
after treatment for one week with the β2 adrenergic antag-
onist ICI daily for seven days. In contrast to this data,
exposure of the breast cancer cell line MDA-MB453 for six
days to the β-adrenergic antagonist propranolol (1 µM)
increased the GIRK1 mRNA levels [10]. Treatment with
the β1 antagonist, atenolol, for the same time period had
no effect, indicating that the β2-adrenergic receptor is
more important for changes in GIRK mRNA. GIRK cur-
rents have been shown to be increased in cells stimulated
with the β-adrenergic agonist Iso in rat atrial myocytes
transfected with β1 or β2 receptors [8]. Heterologous facil-
itation of GIRK currents by β-adrenergic stimulation was
also seen in rat cardiomyocytes [7]. The differences in sig-
naling pathways stimulated by β-adrenergic ligands in
breast cancer and SCLC remain to be elucidated.
Lack of GIRK1 expression in fresh surgical tissue samples of pulm nary adenocarcin mas or pulmonary squamous c rcinomasFigure 7
Lack of GIRK1 expression in fresh surgical tissue 
samples of pulmonary adenocarcinomas or pulmo-
nary squamous carcinomas. Top panel: GIRK1 was not 
expressed in two pulmonary squamous carcinomas or three 
adenocarcinomas obtained from cancer patients. Bottom 
panel: Cyclophilin, used as a positive reaction control was 
seen in all samples. For all gene expression experiments, neg-
ative control reactions were performed and found to be neg-
ative. The bands on the agarose gels were consistent with 
the expected sizes: GIRK1-441 bp; cyclophilin-216 bp; M-100 
bp.
GIRK1 protein expression in SCLC cells that express GIRK1 mRNA as assessed by western blot analysisFigure 8
GIRK1 protein expression in SCLC cells that express 
GIRK1 mRNA as assessed by western blot analysis. In 
the three SCLC cell lines that expressed GIRK1 mRNA (Fig-
ure 1), membrane protein expression was determined. Top 
panel: All three SCLC cell lines (WBA, H69, H146) 
expressed GIRK1 membrane protein. Bottom panel: Actin 
was used as a control for equal sample loading. The bands 
are consistent with the expected size: GIRK1-62 kDa; actin-
42 kDa.
Table 3: Changes in gene expression of GIRK1 after seven day 
treatment of H69 cells with the β2 adrenergic antagonist ICI 118, 
551 (ICI) (100 µM) and lack of changes after seven day treatment 
with β1 adrenergic antagonist atenolol (AT) (100 µM).
Control ICI AT
GIRK1 21.186 ± 0.13 22.040 ± 0.06a 21.238 ± 0.06
18S 12.028 ± 0.17 12.326 ± 0.03 12.090 ± 0.11
Changes in gene expression were determined by real time 
quantitative PCR, and are expressed as threshold values (CT), N = 5. a 
p < 0.0003. Threshold/CT cycle values will be higher for samples with 
less mRNA expression.
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The tobacco carcinogen 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK), a high affinity agonist for β-
adrenergic receptors, stimulated DNA synthesis in two
breast cancer cell lines, an effect inhibited by ICI [9]. In
the present report the β-adrenergic agonist, Iso, inhibited
proliferation in H69 SCLC cells, also indicating opposite
effects between breast cancer and small cell lung cancer
with β-adrenergic agonists. The GIRK channel inhibitor
U5 [28] also inhibited proliferation. It is our contention
that the same receptors and channels (β-adrenergic,
GIRK) are in both breast cancer and lung cancer, and stim-
ulation of these pathways can lead to different results.
This could be important in devising therapies in women
breast cancer patients that are also smokers. Another study
has indicated down-regulation of protein synthesis and
mRNA expression of voltage-dependent and calcium-acti-
vated potassium channels bronchial and bronchiolar
smooth muscle cells in rats by chronic smoking [35]. No
differences were found in protein extracted from the lung,
however.
Further studies are needed with RNA interference (RNAi)
or small interfering RNA (siRNA) and additional β-adren-
ergic agonists and antagonists to further determine the
effects of GIRK1 and GIRK2 on β-adrenergic signaling in
human lung cancer, especially studies on differences in
GIRK protein expression. However, it appears that β-
adrenergic signaling and GIRK channels are important in
both SCLC and breast cancer. These findings may be
important in devising therapies based on β-adrenergic sig-
naling and GIRK channel expression in lung cancers that
express GIRK channels or β-adrenergic receptors.
Conclusion
We feel that this data may indicate that stimulation of
GIRK1 or GIRK2 channels may be important in lung can-
cer. Stimulation of GIRK channels and β-adrenergic sign-
aling may activate similar signaling pathways in both
SCLC and breast cancer, but lead to different results.
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